| Literature DB >> 36186998 |
Xi Xie1, Danyang Yan1, Xin Liu2, Yanjie Wang1, Ying Deng3, Run Yao1, Ning Li1.
Abstract
Background: Platelet distribution width (PDW), as a widely applied and reliable marker of platelet activation, was associated with adverse outcomes in cardiovascular diseases. However, there is little literature on the relationship between PDW and postoperative pneumonia in patients with type A acute aortic dissection (AAAD).Entities:
Keywords: platelet activation; platelet distribution width; postoperative pneumonia; risk factor; type A acute aortic dissection
Year: 2022 PMID: 36186998 PMCID: PMC9521668 DOI: 10.3389/fcvm.2022.984693
Source DB: PubMed Journal: Front Cardiovasc Med ISSN: 2297-055X
Figure 1Flow chart of the study.
Baseline characteristics of AAAD patients by PDW tertiles.
|
|
|
| ||
|---|---|---|---|---|
|
|
|
| ||
|
|
|
| ||
|
| ||||
| Age (years) | 47.25 ± 12.73 | 51.77 ± 10.94 | 50.45 ± 10.11 | 0.06 |
| Gender (female) | 20 (31.25%) | 22 (30.14%) | 15 (20.55%) | 0.29 |
|
| ||||
| Smoking | 32 (50.00%) | 33 (45.21%) | 36 (49.32%) | 0.83 |
| Alcohol consumption | 26 (40.62%) | 27 (36.99%) | 29 (39.73%) | 0.90 |
| Transfusion | 2 (3.12%) | 1 (1.39%) | 1 (1.37%) | 0.70 |
| Marfan syndrome | 7 (10.94%) | 2 (2.74%) | 1 (1.37%) | 0.02 |
| Hypertension | 39 (60.94%) | 54 (73.97%) | 56 (76.71%) | 0.10 |
| Diabetes mellitus | 3 (4.69%) | 5 (6.85%) | 4 (5.48%) | 0.86 |
| COPD | 1 (1.56%) | 4 (5.48%) | 2 (2.74%) | 0.42 |
| Asthma | 0 (0.00%) | 1 (1.37%) | 0 (0.00%) | 0.39 |
| Immunodeficiency | 0 (0.00%) | 0 (0.00%) | 2 (2.74%) | 0.15 |
| Hemopericardium | 11 (17.19%) | 9 (12.33%) | 11 (15.07%) | 0.72 |
| Chronic renal failure | 0 (0.00%) | 1 (1.37%) | 8 (10.96%) | <0.01 |
| Cerebrovascular disease | 2 (3.12%) | 1 (1.37%) | 4 (5.48%) | 0.38 |
| Coronary artery disease | 5 (7.81%) | 12 (16.44%) | 2 (2.74%) | 0.01 |
|
| ||||
| Hb (g/L) | 120.94 ± 19.56 | 123.12 ± 21.83 | 126.22 ± 25.06 | 0.38 |
| Neutrophils (109/L) | 7.81 ± 3.29 | 10.24 ± 3.54 | 10.71 ± 4.19 | <0.01 |
| lymphocyte (109/L) | 1.32 ± 0.56 | 1.12 ± 0.58) | 1.05 ± 0.62 | 0.02 |
| Platelet count (109/L) | 212.72 ± 80.58 | 161.96 ± 75.02 | 155.15 ± 60.27 | <0.01 |
| MPV (fL) | 8.60 ± 1.13 | 9.06 ± 1.31 | 9.01 ± 1.44 | 0.09 |
| hematocrit (%) | 36.07 ± 5.46 | 36.91 ± 6.38 | 37.76 ± 7.23 | 0.31 |
| RDW (%) | 13.97 ± 1.07 | 14.16 ± 1.66 | 14.15 ± 1.79 | 0.72 |
| PT (s) | 13.94 ± 1.45 | 14.49 ± 1.96 | 14.76 ± 3.43 | 0.14 |
| INR | 1.12 ± 0.29 | 1.15 ± 0.16 | 1.19 ± 0.30 | 0.29 |
| APTT (s) | 35.55 (31.53–39.57) | 33.90 (30.30–37.10) | 34.50 (31.30–39.00) | 0.27 |
| D-Dimer (mg/L) | 1.40 (0.71–1.60) | 1.60 (0.94–2.50) | 1.81 (1.45–2.25) | <0.01 |
|
| ||||
| Surgery type | 0.58 | |||
| AAR + TAR (TAVR) + FET | 31 (48.44%) | 37 (50.68%) | 41 (56.16%) | |
| Bentall + TAR (TAVR) + FET | 15 (23.44%) | 12 (16.44%) | 11 (15.07%) | |
| David + TAVR + FET | 4 (6.25%) | 3 (4.11%) | 1 (1.37%) | |
| Combine others | 14 (21.88%) | 21 (28.77%) | 20 (27.40%) | |
| CPB time (min) | 178.00 (163.00–195.00) | 181.00 (156.00–217.00) | 178.00 (162.00–208.00) | 0.69 |
| Duration of ventilator (h) | 33.00 (23.00–73.75) | 45.00 (24.00–74.00) | 45.00 (24.00–72.00) | 0.45 |
| Autologous blood transfusion (≥500 ml) | 18 (28.12%) | 30 (41.67%) | 35 (47.95%) | 0.06 |
| Blood type | 0.50 | |||
| A | 20 (31.25%) | 24 (32.88%) | 22 (30.14%) | |
| B | 7 (10.94%) | 13 (17.81%) | 15 (20.55%) | |
| O | 30 (46.88%) | 33 (45.21%) | 28 (38.36%) | |
| AB | 7 (10.94%) | 3 (4.11%) | 8 (10.96%) | |
| RBCs (unit) | 6.50 (3.88–9.00) | 7.50 (3.00–12.50) | 7.00 (2.00–14.50) | 0.87 |
| Plasma (unit) | 8.45 (5.22–14.00) | 9.50 (4.70–18.00) | 10.50 (6.00–18.00) | 0.14 |
| Cryoprecipitate (therapeutic dose) | 1.00 (0.00–1.00) | 1.00 (0.00–2.00) | 1.00 (1.00–2.00) | 0.13 |
| Platelet (therapeutic dose) | 1.00 (0.00–2.00) | 1.00 (0.00–2.00) | 1.00 (0.00–2.00) | 0.67 |
| Antibiotics | 0.77 | |||
| Quinolone | 1 (1.56%) | 2 (2.74%) | 1 (1.37%) | |
| Penicillin | 59 (92.19%) | 66 (90.41%) | 65 (89.04%) | |
| Cephalosporin | 4 (6.25%) | 4 (5.48%) | 7 (9.59%) | |
| Aminoglycoside | 0 (0.00%) | 1 (1.37%) | 0 (0.00%) | |
| Hospital stay (d) | 16.00 (12.00–18.25) | 15.00 (11.00–19.00) | 16.00 (12.00–19.00) | 0.94 |
| ICU stay (d) | 4.00 (3.00–6.00) | 6.00 (4.00–10.00) | 6.00 (4.00–10.00) | <0.05 |
| Postoperative pneumonia | 8 (12.50%) | 19 (26.03%) | 26 (35.62%) | <0.01 |
Results are expressed as mean ± SD, median (Q1–Q3) or n (%).
P-value < 0.05; COPD, chronic obstructive pulmonary diseases; Hb, hemoglobin; MPV, mean platelet volume; PDW, platelet distribution width; RDW, red blood cell distribution width; PT, prothrombin time; INR, international normalized ratio; APTT, activated partial thromboplastin time; CPB, cardiopulmonary bypass; AAR, ascending aorta replacement; TAR, total arch replacement; TAVR, total aortic vascular replacement; FET, frozen elephant trunk; RBCs, red blood cells; ICU, intensive care unit.
Figure 2Univariate analysis for postoperative pneumonia in patients with AAAD. Only variables associated with postoperative pneumonia were listed (P < 0.10). OR, odds ratio; CI, confidence interval.
Multivariable regressions analysis in different models.
|
|
|
| |
|---|---|---|---|
|
|
|
| |
| PDW (× 10‰) | 1.07 (1.03, 1.12) | 1.07 (1.02, 1.12) | 1.07 (1.02, 1.13) |
| <17.2 | Ref | Ref | Ref |
| ≥17.2 | 2.28 (1.21, 4.30) | 2.17 (1.15, 4.13) | 2.39 (1.13, 5.06) |
| T1 (14.80–16.70) | Ref | Ref | Ref |
| T2 (16.80–17.30) | 2.46 (0.99, 6.10) | 2.54 (1.01, 6.40) | 2.21 (0.73, 6.72) |
| T3 (17.40–19.80) | 3.87 (1.60, 9.36) | 3.77 (1.53, 9.24) | 4.16 (1.40, 12.33) |
| <0.01 | <0.01 | <0.01 |
OR, odds ratio; CI, confidence interval.
P-value < 0.05. Model I adjust for: none. Model II adjust for: age; gender. Model III adjust for: age; gender; neutrophils; hematocrit; duration of ventilator; RBCs; plasma; cryoprecipitate; hospital and ICU stay.
Figure 3Smoothing spline fitting curve. Adjusted variables: age; gender; neutrophils; hematocrit; duration of ventilator; RBCs; plasma; cryoprecipitate; hospital and ICU stay. The linear plots are displayed with red dotted lines, and the blue dotted lines represent 95% CI.